Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

Shinichi Ohkawa

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5042661824, A5111444625, A5111616957. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
119
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 6 papers · 2016: 5 papers · 2017: 4 papers · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers

Papers 32

  1. Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. Co-author DOI 10.1080/01635581.2020.1871495↗
  2. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  3. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  4. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… Co-author DOI 10.2169/internalmedicine.2362-18↗
  5. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Co-author DOI 10.1097/mpa.0000000000001052↗
  6. A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer pat… Co-author DOI 10.1136/bmjgast-2017-000187↗
  7. Prediction model for pancreatic cancer risk in the general Japanese population. Co-author DOI 10.1371/journal.pone.0203386↗
  8. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pa… Co-author PMID 30416859↗
  9. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  10. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  11. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  12. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  13. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.12.362↗
  14. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Co-author DOI 10.1016/j.pan.2016.07.007↗
  15. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Ca… Co-author DOI 10.1159/000446989↗
  16. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. Co-author DOI 10.1186/s12876-016-0503-7↗
  17. Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by t… Co-author PMID 27069182↗
  18. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.07.003↗
  19. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  20. Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. First author DOI 10.1038/srep17018↗
  21. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global ra… Co-author DOI 10.1093/jjco/hyv011↗
  22. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  23. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Co-author DOI 10.1111/cas.12709↗
  24. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Co-author DOI 10.1007/s00280-014-2601-y↗
  25. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1111/cas.12501↗
  26. Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan. Co-author DOI 10.7314/apjcp.2014.15.1.391↗
  27. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  28. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with su… Co-author DOI 10.1016/j.ejso.2012.08.008↗
  29. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adju… Co-author DOI 10.1245/s10434-011-2054-z↗
  30. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗
  31. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyr090↗
  32. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗

Closest collaborators

The 25 strongest of 119 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 13 shared papers, 2014–2022 · strength 0.92
  2. Manabu Morimoto · 9 shared papers, 2014–2022 · strength 0.66
  3. Junji Furuse · 14 shared papers, 2011–2019 · strength 0.65
  4. Takuji Okusaka · 14 shared papers, 2011–2018 · strength 0.57
  5. Satoshi Kobayashi · 7 shared papers, 2014–2022 · strength 0.54
  6. Tatsuya Ioka · 11 shared papers, 2011–2019 · strength 0.52
  7. Hiroshi Ishii · 10 shared papers, 2014–2018 · strength 0.49
  8. Narikazu Boku · 9 shared papers, 2011–2017 · strength 0.36
  9. Masafumi Ikeda · 7 shared papers, 2013–2019 · strength 0.35
  10. Soichiro Morinaga · 6 shared papers, 2012–2022 · strength 0.33
  11. Hideki Ueno · 6 shared papers, 2013–2019 · strength 0.33
  12. Shun Tezuka · 4 shared papers, 2016–2022 · strength 0.32
  13. Akihiro Funakoshi · 8 shared papers, 2011–2017 · strength 0.27
  14. Masao Tanaka · 5 shared papers, 2013–2017 · strength 0.24
  15. Taketo Yamaguchi · 5 shared papers, 2013–2017 · strength 0.22
  16. Yasuo Ohashi · 5 shared papers, 2013–2017 · strength 0.22
  17. Kenji Yamao · 6 shared papers, 2011–2017 · strength 0.22
  18. Yuichiro Tozuka · 2 shared papers, 2018–2022 · strength 0.21
  19. Shin Maeda · 2 shared papers, 2018–2022 · strength 0.21
  20. Naoto Egawa · 5 shared papers, 2014–2018 · strength 0.20
  21. Akira Fukutomi · 5 shared papers, 2013–2015 · strength 0.20
  22. Nobumasa Mizuno · 3 shared papers, 2015–2019 · strength 0.18
  23. Hiroyuki Isayama · 4 shared papers, 2014–2017 · strength 0.18
  24. Shoji Nakamori · 5 shared papers, 2011–2017 · strength 0.18
  25. Sawako Kuruma · 4 shared papers, 2014–2018 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.